Collateral for a security interest recorded Sep 11, 2026 (Truist Bank).
Term ends Jul 27, 2032 · Low confidence
20-year base term ends Dec 9, 2037
Held by Commave Therapeutics S.A.
Filed Dec 8, 2020 as application 17/115,425 · Granted Nov 22, 2022
Base term plus 56 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2017
2037
Clock starts
Dec 9, 2017
Dec 9, 2017
Term ends
Jul 27, 2032
Jul 27, 2032
Granted
Nov 22, 2022
Nov 22, 2022
base term
after the term ends
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
56
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 10,584,112, US 10,584,113, US 10,759,778, US 10,954,212, US 9,079,928.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
11
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 56 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 2 maintenance fees is paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 9, 2017, when application PCT/US2017/065482, the earliest non-provisional in its chain, was filed (this one was filed Dec 8, 2020); a parent in its chain could not be resolved (the next row) | Dec 9, 2037 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +56 days, USPTO patent term adjustment record | Feb 3, 2038 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,584,112, US 10,584,113, US 10,759,778, US 10,954,212, US 9,079,928) | capped to Jul 27, 2032 | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jul 27, 2032 | Low confidence |
This family
| US 10,584,113 | In force no later than Dec 2037 | no later than Dec 2037 |
| US 10,584,112 | In force no later than Dec 2037 | no later than Dec 2037 |
| US 10,759,778 | In force Dec 2037 | Dec 2037 |
| US 11,021,459 | In force Dec 2037 | Dec 2037 |
| US 11,021,460 | In force Dec 2037 | Dec 2037 |
| US 10,954,212 | In force Dec 2037 | Dec 2037 |
| US 10,954,213 | In force Dec 2037 | Dec 2037 |
| US 10,858,341 | In force Dec 2037 | Dec 2037 |
8 of 11 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 14, 2021 Reel 54920, frame 66 | Mickle, Travis; Guenther, Sven; Chi, Guochen | Kempharm, Inc. | Assignment of Assignor's Interest |
| Apr 8, 2024 Reel 67040, frame 637 | Zevra Therapeutics, Inc. | Alter Domus (US) LLC | Security Interest |
| Mar 13, 2026 Reel 75080, frame 907 | Alter Domus (US) LLC | Zevra Therapeutics, Inc. | Release of Security Interest |
| Mar 25, 2026 Reel 75243, frame 8 | Kempharm, Inc. | Zevra Therapeutics, Inc. | Change of Name |
| Mar 25, 2026 Reel 74186, frame 531 | Zevra Therapeutics, Inc. | Commave Therapeutics S.A. | Assignment of Assignor's Interest |
| Mar 26, 2026 Reel 74195, frame 8 | Zevra Therapeutics, Inc. | Commave Therapeutics S.A. | Assignment of Assignor's Interest |
| Sep 11, 2026 Reel 75980, frame 787 | Commave Therapeutics S.A. | Truist Bank, As Administrative Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jul 2032
Term ends Jul 27, 2032. Maintenance fees still fall due before then
Note
The 56 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,584,112, US 10,584,113, US 10,759,778, US 10,954,212, US 9,079,928.
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.